These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Psychologic evaluation of amantadine treatment of parkinsonism and comparative analysis of the effects with L-dopa]. Puca FM; Micalizzi V; Megna GF; Barbieri NF; Pigneri MT Acta Neurol (Napoli); 1971; 26(6):707-30. PubMed ID: 4946491 [No Abstract] [Full Text] [Related]
44. [Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease]. Hacohen H; Gurtner B Schweiz Med Wochenschr; 1972 Apr; 102(16):583-6. PubMed ID: 5019377 [No Abstract] [Full Text] [Related]
45. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine]. Sigwald J; Raymondeaud C; Piot C Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718 [No Abstract] [Full Text] [Related]
46. [Effectiveness of a combination therapy in the Parkinson syndrome by amantadine hydrochloride and anticholinergic agents]. Gospavić J; Vidaković Z Srp Arh Celok Lek; 1974 Jun; 102(6):447-57. PubMed ID: 4450143 [No Abstract] [Full Text] [Related]
49. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease. Schwab RS; England AC Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453 [No Abstract] [Full Text] [Related]
50. [Catecholamine excretion and treatment of parkinsonism with midantan]. Kandel' EI; Iadgarov IS Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Sep; 76(9):1323-6. PubMed ID: 1015136 [No Abstract] [Full Text] [Related]
52. [Combined therapy of parkinsonism using amantadine]. Umbach W; Oppel F Munch Med Wochenschr; 1973 Apr; 115(14):604-7. PubMed ID: 4740225 [No Abstract] [Full Text] [Related]
53. [Present-day treatment of parkinsonism in the aged]. Siegfried J Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539 [No Abstract] [Full Text] [Related]
54. The management of parkinsonism. N Z Med J; 1971 Jul; 74(470):36-7. PubMed ID: 5289750 [No Abstract] [Full Text] [Related]
55. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Bauer RB; McHenry JT Neurology; 1974 Aug; 24(8):715-20. PubMed ID: 4858417 [No Abstract] [Full Text] [Related]
56. [Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine)]. Campanella G; Carrieri P; Romito D; Pasqual-Marsettin E Acta Neurol (Napoli); 1973; 28(1):1-34. PubMed ID: 4704396 [No Abstract] [Full Text] [Related]
57. The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy. Giuffrè R; Gambacorta D Eur Neurol; 1971; 5(5):311-6. PubMed ID: 4943872 [No Abstract] [Full Text] [Related]
58. [Principles for amantadine therapy in parkinsonism]. Gilland O Lakartidningen; 1972 Nov; 69(46):5343-5. PubMed ID: 4650743 [No Abstract] [Full Text] [Related]
59. The comparative value of amantadine and levodopa. Dallos V; Heathfield K; Stone P; Allen F Postgrad Med J; 1972 Jun; 48(560):354-8. PubMed ID: 4558895 [TBL] [Abstract][Full Text] [Related]
60. [Treatment of parkinsonism with L-dopa]. Presthus J Nord Med; 1970 Nov; 84(46):1467-8. PubMed ID: 5479940 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]